Traws Pharma, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Traws Pharma, Inc. (TRAW) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $117.46 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-04-15
- Traws Pharma, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $0.00.
- Traws Pharma, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $0.00.
- Traws Pharma, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-06-30 was $117.46M.
- Traws Pharma, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $117.46M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-15 | $117.46M derived: sum of 3 quarters · filed 2026-04-15 | $117.46M 10-K · filed 2026-04-15 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $117.46M derived: sum of 2 quarters · filed 2025-11-13 | $117.46M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $117.46M 10-Q · filed 2025-08-14 | $117.46M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |